Background. Febrile neutropenia (FN) is a common complication to chemotherapy associated with a high burden of morbidity and mortality. Reliable prediction of individual risk based on pretreatment risk factors allows for stratification of preventive interventions. We aimed to develop such a risk stratification model to predict FN in the 30 days after initiation of chemotherapy.
Background. Febrile neutropenia (FN) is a common complication to chemotherapy associated with a high burden of morbidity and mortality. Reliable prediction of individual risk based on pretreatment risk factors allows for stratification of preventive interventions. We aimed to develop such a risk stratification model to predict FN in the 30 days after initiation of chemotherapy.
Methods. We included consecutive treatment-naïve patients with solid cancers and diffuse large B-cell lymphomas at Copenhagen University Hospital, 2010-2015. Data were obtained from the PERSIMUNE repository of electronic health records. FN was defined as neutrophils ≤0.5 × 10E9/L at the time of either a blood culture sample or death. Time from initiation of chemotherapy to FN was analyzed using FineGray models with death as a competing event. Risk factors investigated were: age, sex, body surface area, haemoglobin, albumin, neutrophil-to-lymphocyte ratio, Charlson Comorbidity Index (CCI) and chemotherapy drugs. Parameter estimates were scaled and summed to create the risk score. The scores were grouped into four: low, intermediate, high and very high risk.
Results. Among 8,585 patients, 467 experienced FN, incidence rate/30 person-days 0.05 (95% CI, 0.05-0.06). Age (1 point if > 65 years), albumin (1 point if < 39 g/L), CCI (1 point if > 2) and chemotherapy (range -5 to 6 points/drug) predicted FN. Median score at inclusion was 2 points (range -5 to 9). The cumulative incidence and the incidence rates and hazard ratios of FN are shown in Figure 1 and Table 1 , respectively.
Conclusion. We developed a risk score to predict FN the first month after initiation of chemotherapy. The score is easy to use and provides good differentiation of risk groups; the score needs independent validation before routine use.
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No reported disclosures. Results. Charts of 250 patients who received treatment with Ibrutinib were reviewed. Thirty-six excluded as they were lost to follow-up or received less than 30 days of Ibrutinib therapy. Among the 214 patients included, mean age was 65 (range 31-92) years and 161 (75%) were men. Eleven patients (5.1%) developed infection during the follow-up period: six cases of invasive aspergillosis (IA) (six pulmonary and one also involved the central nervous system (CNS)), twp cases of methicillin-resistant Staphylococcus aureus pneumonia, one case of CNS cryptococcal meningitis, one PJP Pneumonia, and one disseminated zoster (CNS meningoencephalitis). Of the 11 patients who developed infection, none was neutropenic at the time of infection and none received substantial corticosteroid courses. Apart from one patient who received combination therapy with ofatumumab, all patients who developed infection were receiving Ibrutinib monotherapy prior to the onset of infection.
Infections in Patients Receiving
Conclusion. Our data demonstrate that patients receiving Ibrutinib therapy for lymphoid malignancies are at risk for serious infections, including invasive fungal infections. The majority of infections in these patients developed in the absence of other risk factors for infection, suggesting that Ibrutinib may be independently associated with increased risk for certain infections.
